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Abstract 
 
Opportunistic fungal infections have been occurring with increasing frequency in recent 
years in immunocompromised patients. Several data were published in the last decade about the 
clinical importance of the filamentous fungal genus Trichoderma, indicating, that Trichoderma 
strains - besides their agricultural and biotechnological importance - may be potential 
opportunistic pathogens of immunocompromised hosts as well. This review is going to 
summarize the clinical case reports about Trichoderma infections, and discuss the information 
available on the antifungal susceptibility and on the ecophysiological, enzymological and 
systematic aspects of clinical Trichoderma isolates.  
 
Introduction 
 
Trichoderma species are imperfect filamentous fungi with teleomorphs belonging to the 
Hypocreales order of the Ascomycota division. The ecological role of this genus is that 
Trichoderma strains take part in the decomposition of plant residues in the soil. Some 
Trichoderma species are very good cellulase producers and therefore they are important for the 
biotechnological industry [1, 2]. The agricultural importance of the genus is that some 
Trichoderma species possess good antagonistic abilities against plant pathogenic fungi [3-5]. 
Trichoderma strains with effective antagonistic abilities are potential candidates for the 
biological control of plant diseases [6, 7].  
Trichoderma species have been reported as pathogens of reptiles [8, 9], and in increasing 
number of cases as etiologic agents in human infections. The spectrum of opportunistic fungi is 
widening as a result of the rising number of immunocompromised patients. The genus 
Trichoderma is already on the growing list of potential fungal pathogens in 
immunocompromised hosts.  
 
Case reports about Trichoderma infections in the literature 
 
Six species of the genus Trichoderma (T. citrinoviride, T. harzianum, T. koningii, T. 
longibrachiatum, T. pseudokoningii and T. viride) have been identified as etiologic agents of 
infections in immunocompromised patients. Detailed case reports about Trichoderma infections 
are summarized in Table I. 
Numerous cases of peritonitis have been reported in peritoneal dialysis patients with T. 
harzianum [10], T. koningii [11, 12], T. longibrachiatum [13], T. pseudokoningii [14], T. viride 
[15, 16] and an unidentified Trichoderma species [17]. The causative agent was isolated from the 
peritoneal effluent in all of these cases. Three of the patients survived [11, 14, 17], the early 
catheter removal proved to be a succesfull therapy. 
 The number of cases of Trichoderma infection in immunocompromised transplant 
recipients is also significant. A fatal infection caused by a T. pseudokoningii strain was described 
in a leukemia patient after bone marrow transplantation. The fungus was isolated from specimens 
obtained by bronchoalveolar lavage and skin biopsy. Autopsy has shown that the infection was 
disseminated: hyphae were present in the lungs, brain, heart, stomach and pretracheal abscesses 
[18]. A fatal disseminated T. longibrachiatum infection occured in a patient who had received an 
allogenic bone marrow transplant for acute lymphoblastic leukemia. The fungus was recovered 
from a perirectal ulcer biopsy and stool surveillance cultures, suggesting the gastrointestinal tract 
as the portal of entry [19]. A liver transplant recipient developed infection of a perihepatic 
haematoma due to T. viride. The fungus was found to be persistent in the immunocompromised 
host despite amphotericin B treatment and surgical removal of the infected haematoma, however, 
the patient died of unrelated complications [20]. The acute invasive sinusitis caused by T. 
longibrachiatum in a liver and small bowel transplant recipient was succesfully treated with 
surgical debridements and amphotericin B followed by oral itraconazole [21]. Guarro et al. 
detected a systemic T. harzianum infection in the autopsy study of a renal transplant recipient 
[22], the fungus was recovered from abscesses in brain and lung tissues. 
The isolation of T. longibrachiatum was reported in further cases: from an infection of the 
skin and subcutaneous tissue in a pediatric patient with severe aplastic anemia and neutropenia 
[23], from a brain abscess in a leukemic patient with prolonged neutropenia [24], from otitis 
externa in a child [25] and from a HIV-positive patient (American Type Culture Collection, 
ATCC 208859, [26]). Another case of Trichoderma infection connected with AIDS was reported 
recently [27]. T. viride was found in several specimens of sputum of a patient with pulmonary 
mycetoma [28] and Trichoderma species were involved in cases of mycotic keratitis [29] and 
endocarditis [30] as well.  
There is a lack of published case reports in the case of other clinical Trichoderma isolates 
deposited at the University of Alberta Microfungus Collection and Herbarium (T. 
longibrachiatum UAMH 9515 from the peritoneal effluent of a female and T. citrinoviride 
UAMH 9573 from a peritoneal catheter tip), at the Canadian Collection of Fungal Cultures (T. 
pseudokoningii CCFC 007753 and CCFC 007754 isolated from a bone marrow transplant 
recipient and from a liver and bowel transplant recipient, respectively), and at Centraalbureau 
voor Schimmelcultures (T. longibrachiatum CBS 446.95 isolated from the lung of a patient, who 
died). Further clinical Trichoderma strains were sent to the the National Reference Center of 
Mycoses and Antifungal Drugs at the Institute Pasteur: T. longibrachiatum IP-92 0647 from a 
patient with acute leukemia, IP-94 0958 from a patient who had a lung transplantation, IP-96 
0086 from a haematic wound of an otherwise healthy patient, IP-93 1282 isolated from a 
bronchoalveolar washing in a 2-month bone marrow recipient, IP-93 1792 obtained from a 
cerebrospinal derivative catheter, IP-94 1510 from infected maxillar sinus, IP-97 0711 from the 
liquid of a chylothorax and T. citrinoviride IP-95 1151 from blood cultures of a patient in aplasia 
associated with lymphoma). Five T. longibrachiatum isolates originated from different patients 
were received at the Medical Mycology Research Laboratory, Medical College of Virginia, 
Virginia Commonwealth University between 1996 and 2001, and examined by Espinel-Ingroff 
along with other emerging pathogenic filamentous fungi [31, 32]. It is also conceivable, that 
further Trichoderma infections have not been documented. 
 Most of the clinical Trichoderma strains involved in infections were isolated from 
immunocompromised patients. An exception is the case of an inadvertent infusion of T. viride to 
an immunocompetent host with contaminated intravenous fluid. The patient remained well after 
24 hours of amphotericin B treatment [33]. 
 Data indicate that members of the genus Trichoderma may also be present as the part of 
the human microflora. Strains were isolated from sputum (T. koningii UAMH 473 and UAMH 
475) and from sinus ethmoidalis (T. pseudokoningii CBS 500.94). Buzina et al. isolated a T. 
viride strain from the nasal mucus of a healthy patient and a T. inhamatum strain from a chronic 
rhinosinusitis (CRS) patient, however, great number of other fungi were found to be associated 
with CRS and it is still not known, which of them are responsible for the eosinophilic reaction 
[34]. The possible involvement of Trichoderma species in eosinophil activation was already 
demonstrated: precipitating antibodies against T. viride were detected in the sera of patients with 
acute eosinophilic pneumonia [35, 36]. It is also known that T. viride potentiates IgE-related 
histamine release from human bronchoalveolar cells, suggesting the possible involvement of the 
genus in allergic reactions [37]. 
Susceptibility of clinical Trichoderma isolates to antifungal compounds 
 
Antifungal susceptibility testing of fungi involved in opportunistic infections is relevant 
for the choice of adequate therapy. Data available about the susceptibilities of clinical 
Trichoderma isolates - including our Etest results about the susceptibilities of strains T. 
citrinoviride UAMH 9573, T. koningii CM 382 ([38], kindly provided by the Centro Nacional de 
Microbiologia, Immunologia y Virologia Sanitaria, mycology section, Majadahonda, Madrid), T. 
longibrachiatum ATCC 201044 [23], ATCC 208859, UAMH 7955 [21], UAMH 7956 [19] and 
UAMH 9515 - are summarized in Table II. Different methods were applied for the determination 
of the minimal inhibitory concentration (MIC) values of the antifungal agents in the available 
studies [39-44].  
Most isolates proved to be resistant to fluconazole and 5-fluorocytosine (5FC), and 
susceptible or intermediate to amphotericin B, itraconazole, ketoconazole and miconazole, 
however, amphotericin B resistance [11, 12, 13, 25] and high MIC-levels of itraconazole [22, 25, 
38] and ketoconazole [22] were also reported in certain cases. Antimycotic activity with the disc 
method revealed apparent susceptibility to voriconazole in the case of five examined isolates 
[38]. The low susceptibility level of some clinical Trichoderma isolates to antifungal drugs may 
cause difficulties in the therapy of infected patiens. In cases of suspected or confirmed 
Trichoderma infection, amphotericin B alone or in combination with itraconazole or 
ketoconazole is suggested as an adequate choice of treatment, the duration of which should be 
individualized to each case according to the type and extent of the infection and underlying 
predisposing conditions [23].  
 
Ecophysiological and enzymological investigation of clinical Trichoderma isolates 
 
Several data are available about the ecophysiological and enzymological properties of 
mycoparasitic Trichoderma strains with biocontrol potential [45-49], however, there is a lack of 
similar studies on clinical Trichoderma isolates.  
We examined the ecophysiological features of strains T. citrinoviride UAMH 9573, T. 
koningii CM 382, T. longibrachiatum ATCC 201044, ATCC 208859, UAMH 7955, UAMH 
7956 and UAMH 9515. The influence of temperature and pH on linear mycelial growth was 
studied on both minimal and yeast extract agar media [38]. All of the strains were able to grow 
on these media at temperatures ranging from 10 to 40 °C, with an optimum at 30 °C. Studies on 
the ecophysiology of the genus Trichoderma concluded, that species belonging to the 
Longibrachiatum section of the genus Trichoderma (including T. citrinoviride and T. 
longibrachiatum) have higher optimum growth temperatures [26, 50, 51]. Because growth at 
elevated temperatures is one of the virulence factors of fungi, it is not surprising, that most of the 
strains involved in Trichoderma infections are belonging to the Longibrachiatum section of the 
genus. The pH ranging from 2.0 to 9.0 supported the growth of most of the examined strains at 
25 °C, with an optimum at pH 4. At elevated temperature (37 °C) the range was narrower, but all 
of the clinical strains were able to grow at physiological pH, which ability can promote their 
growth as facultative human pathogens [38].  
The utilization of 80 compounds as carbon sources, and 34 compounds as nitrogen 
sources were also investigated. A series of amino acids, e.g. L-asparagine, L-aspartic acid, L-
glutamine, L-glutamic acid, L-ornithine, γ-amino-butyric acid and N-acetyl-D-glucosamine were 
utilized by all of the examined clinical Trichoderma strains both as carbon and nitrogen source 
[38]. 
We examined the extracellular proteolytic enzyme activities in the supernatants of 
induced cultures of strains T. citrinoviride UAMH 9573, T. koningii CM 382, T. 
longibrachiatum UAMH 7955, UAMH 7956 and UAMH 9515 by Sephadex G-100 column 
chromatography [52]. Trypsin-like protease, chymotrypsin-like protease and Leu-aminopeptidase 
activities cleaving N-Benzoyl-Phe-Val-Arg-p-nitroanilide, N-Succinyl-Ala-Ala-Pro-Phe-p-
nitroanilide and L-Leu-p-nitroanilide, respectively, were found to be common among the 
examined strains. However, strain T. koningii CM 382 has not produced any trypsin-like and 
chymotryopsin-like proteases and only limited chymotrypsin-like and Leu-aminopeptidase 
activities were present in the culture supernatant of strain T. longibrachiatum UAMH 9515. 
Sephadex G-100 profiles of these three types of proteolytic enzyme activities proved to be 
complex suggesting the presence of more isoenzymes. The isoenzyme profiles were found to be 
dependent on the culturing conditions in many cases. Different Leu-aminopeptidase isoenzymes 
were secreted by Trichoderma citrinoviride UAMH 7956 at pH 5.0 and pH 7.0. In the case of 
some strains, the activities of certain proteases proved to be higher in the ferment broths of 
induced cultures shaken at 37 °C than of those shaken at 25 °C. Proteases with such 
characteristics may be involved in the virulence of opportunistic Trichoderma strains [52]. 
 
Systematic studies on clinical Trichoderma isolates 
 
 The appropriate identification of the fungal etiologic agents involved in opportunistic 
infections is crucial for the adequate choice of specific therapeutic interventions. Several clinical 
Trichoderma isolates were identified on the basis of morphological characteristics [e.g. 12, 18, 
22]. As the identification of Trichoderma strains is difficult if only morphological characters are 
considered, the identity of some clinical Trichoderma isolates was confirmed by molecular 
techniques, like DNA-fingerprinting [19, 21, 23], or the sequencing of ribosomal DNA internal 
transcribed spacer region ITS-1 – 5.8S - ITS-2 [19, 24, 25]. Kuhls et al. [53] used PCR-
fingerprinting to identify six human pathogenic Trichoderma isolates - including two strains 
from reported cases [18, 24] - as T. longibrachiatum (5 isolates) and T. citrinoviride (1 isolate). 
Sequencing experiments of the ITS-region confirmed the identifications made on the basis of 
PCR-fingerprinting data. The results of this study revealed that it is necessary to reidentify a 
morphologically identified clinical T. pseudokoningii strain [18] as T. longibrachiatum. 
 As the most of the clinical Trichoderma isolates belong to the section Longibrachiatum of 
the genus Trichoderma, we plan to examine clinical and saprophytic T. longibrachiatum and T. 
citrinoviride isolates with the method of Random Amplified Polymorphic DNA (RAPD). Such 
studies may reveal characteristic RAPD-bands for the discrimination between the section 
Longibrachiatum and other sections, and between clinical and saprophytic isolates within the 
Longibrachiatum section, enabling the design of specific primers of diagnostic value for the rapid 
identification of clinical Trichoderma isolates. 
 
Conclusions 
 
In immunocompromised patients, Trichoderma strains are able to cause diseases varying 
from localized infections to fatal disseminated diseases. Most of the cases are reported from 
patients undergoing peritoneal dialysis and from transplant recipients. T. longibrachiatum is the 
most frequently occuring etiologic agent within the genus. The detailed case reports and data 
about the antifungal susceptibilities of clinical Trichoderma isolates reveal useful information 
for the planning of the therapy in cases of suspected or confirmed Trichoderma infections. 
The ecophysiological and enzymological investigation of clinical Trichoderma isolates 
may result in better understanding of their virulence factors. Growth at elevated temperatures, 
the ability to tolerate neutral pH and to utilize amino acids as carbon and nitrogen sources, as 
well as the production of extracellular proteolytic enzymes are among the potential virulence 
factors of Trichoderma strains involved in opportunistic infections. Other factors, like the 
hydrophobicity of conidia, melanic or carotenoid pigments and mycotoxins are also among the 
possible virulence factors of fungal opportunists [54]. 
The identification of Trichoderma species is difficult based on morphological characters 
only, therefore the identity of clinical isolates is suggested to be confirmed by molecular 
techniques. Furthermore, molecular methods may reveal diagnostic tools for rapid species 
identification in the clinical practice. 
 
Acknowledgement. This work was supported by grant OTKA F037663 of the Hungarian 
Scientific Research Fund. 
  
REFERENCES 
 
1. Réczey,K., Szengyel,Z., Eklund,R., Zacchi,G.: Cellulase production by T. reesei. Bioresource 
Technol 57, 25–30 (1996). 
2. Juhász,T., Kozma,K., Szengyel,Z., Réczey,K.: Production of β-glucosidase by mixed culture 
of Aspergillus niger BKMF 1305 and Trichoderma reesei RUT C30. Food Technol 
Biotechnol in press (2003). 
3. Sivan,A., Chet, I.: Biological control of Fusarium spp. in cotton, wheat and muskmelon by 
Trichoderma harzianum. J Phytopathol 116, 39-47 (1986). 
4. Naár,Z., Kecskés,M.: A method for selecting Trichoderma strains antagonistic against 
Sclerotinia minor. Microbiol Res 150, 239-246 (1995). 
5. Naseby,D.C., Pascual,J.A., Lynch,J.M.: Effect of biocontrol strains of Trichoderma on plant 
growth, Pythium ultimum populations, soil microbial communities and soil enzyme 
activities. J Appl Microbiol 88, 161-169 (2000). 
6. Papavizas,G.C.: Trichoderma and Gliocladium: biology, ecology, and potential for biocontrol. 
Annu Rev Phytopathol 23, 23-54 (1985). 
7. Manczinger,L., Antal,Z., Kredics,L.: Ecophysiology and breeding of mycoparasitic 
Trichoderma strains. Acta Microbiol Immunol Hung 49, 1–14 (2002). 
8. Foreyt,W.J., Leathers,C.W.: Trichoderma sp. infection in the alligator (Alligator 
mississippiensis). J Herpetol 19, 530-531 (1985). 
9. Jacobson,E.R.: Necrotizing mycotic dermatitis in snakes: clinical and pathologic features. J 
Am Vet Med Assoc 177, 838-841 (1980). 
10. Guiserix,J., Ramdane,M., Finielz,P., Michault,A., Rajaonarivelo,P.: Trichoderma harzianum 
peritonitis in peritoneal dialysis. Nephron 74, 473-474 (1996). 
11. Ragnaud,J.M., Marceau,C., Roche-Bezian,M.C., Wone,C.: Infection peritoneale a 
Trichoderma koningii sur dialyse peritoneale continue ambulatoire. Med Maladies Infect 7, 
402-405 (1984). 
12. Campos-Herrero,M.I., Bordes,A., Perera,A., Ruiz,M.C., Fernandez,A.: Trichoderma koningii 
peritonitis in a patient undergoing peritoneal dialysis. Clin Microbiol Newslett 18, 150-151 
(1996).  
13. Tanis,B.C., van der Pijl,H., van Ogtrop,M.L., Kibbelaar,R.E., Chang,P.C.: Fatal fungal 
peritonitis by Trichoderma longibrachiatum complicating peritoneal dialysis. Nephrol Dial 
Transplant 10, 114-116 (1995). 
14. Rota,S., Marchesi,C., Farina,C., de Biévre,C.: Trichoderma pseudokoningii peritonitis in 
automated peritoneal dialysis patient succesfully treated by early catheter removal. Perit Dial 
Int 20, 91-94 (2000). 
15. Loeppky,C.B., Sprouse,R.F., Carlson,J.V., Everett,E.D.: Trichoderma viride peritonitis. South 
Med J 76, 798-799 (1983). 
16. Warnock,D.W., Johnson,E.M.: Clinical manifestation and management of 
hyalohyphomycosis, phaehyphomycosis and other uncommon forms of fungal infection in the 
compromised patient. In: Warnock,D.W., Richardson,M.D. (eds): Fungal infection in the 
compromised patient. Chichester: John Wiley & Sons Ltd, 1991, pp 248-310 
17. Bren,A.: Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Eur J 
Clin Microbiol Infect Dis 17, 839-843 (1998). 
18. Gautheret,A., Dromer,F., Bourhis,J.-H., Andremont,A.: Trichoderma pseudokoningii as a 
cause of fatal infection in a bone marrow transplant recipient. Clin Infect Dis 20, 1063-1064 
(1995). 
19. Richter,S., Cormican,M.G., Pfaller,M.A., Lee,C.K., Gingrich,R., Rinaldi,M.G., Sutton,D.A.: 
Fatal disseminated Trichoderma longibrachiatum infection in an adult bone marrow 
transplant patient: Species identification and review of the literature. J Clin Microbiol 37, 
1154-1160 (1999). 
20. Jacobs,F., Byl,B., Bourgeois,N., Coremans-Pelseneer,J., Florquin,S., Depré,G., Van de 
Stadt,J., Adler,M., Gelin,M., Thys,J.P.: Trichoderma viride infection in a liver transplant 
recipient. Mycoses 35, 301-303 (1992). 
21. Furukawa,H., Kusne,S., Sutton,D.A., Manez,R., Carrau,R., Nichols,L., Abu-Elmagd,K., 
Skedros,D., Todo,S., Rinaldi,M.G.: Acute invasive sinusitis due to Trichoderma 
longibrachiatum in a liver and small bowel transplant recipient. Clin Infect Dis 26, 487-489 
(1998). 
22. Guarro,J., Antolin-Ayala,M.I., Gene,J., Gutierrez-Calzada,J., Nieves-Diez,C., Ortoneda,M.: 
Fatal case of Trichoderma harzianum infection in a renal transplant recipient. J Clin 
Microbiol 37, 3751-3755 (1999). 
23. Munoz,F.M., Demmler,G.J., Travis,W.R., Ogden,A.K., Rossmann,S.N., Rinaldi,M.G.: 
Trichoderma longibrachiatum infection in a pediatric patient with aplastic anemia. J Clin 
Microbiol 35, 499-503 (1997). 
24. Seguin,P., Degeilh,B., Grulois,I., Gacouin,A., Maugendre,S., Dufour,T., Dupont,B., 
Camus,C.: Successful treatment of a brain abscess due to Trichoderma longibrachiatum 
after surgical resection. Eur J Clin Microbiol Infect Dis 14, 445-448 (1995). 
25. Hennequin,C., Chouaki,T., Pichon,J.C., Strunski,V., Raccurt,C.: Otitis externa due to 
Trichoderma longibrachiatum. Eur J Clin Microbiol Infect Dis 19, 641-642 (2000). 
26. Samuels,G.J., Petrini,O., Kuhls,K., Lieckfeldt,E., Kubicek,C.P.: The Hypocrea schweinitzii 
complex and Trichoderma sect. Longibrachiatum. Stud Mycol 41, 1-54 (1998). 
27. Amato,J.G., Amato,V.S., Amato Neto,V., Heins-Vaccari,E.M.: [An AIDS patient with 
Trichoderma]. Rev Soc Brasil Med Tropic 35(3), 269 (2002). 
28. Escudero,C.M.R., Pino Corral,E., Munoz,R.: Micoma pulmonar causado por Trichoderma 
viride. Actas Dermosifiliogr 67, 673-680 (1976). 
29. Venugopal,P.L., Venugopal,T.L., Gomathi,A., Ramakrishna,E.S., Ilavarasi,S.: Mycotic 
keratitis in Madras. Indian J Pathol Microbiol 32, 190-197 (1989). 
30. Bustamante-Labarta,M.H., Caramutti,V., Allende,G.N., Weinschelbaum,E., Torino,A.F.: 
Unsuspected embolic fungal endocarditis of an aortic conduit diagnosed by transesophageal 
echocardiography. J Am Soc Echocardiogr 13, 953-954 (2000). 
31. Espinel-Ingroff,A.: In vitro fungicidal activities of voriconazole, itraconazole, and 
amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 
39, 954-958 (2001). 
32. Espinel-Ingroff,A.: Comparison of the Etest with the NCCLS M38-P method for antifungal 
susceptibility testing of common and emerging pathogenic filamentous fungi. J Clin 
Microbiol 39, 1360-1367 (2001). 
33. Robertson,M.H.: Fungi in fluids - a hazard of intravenous therapy. J Med Microbiol 3, 99-
102 (1970). 
34. Buzina,W., Braun,H., Freudenschuss,K., Lackner,A., Schimpl,H., Stammberger,H.: 
Biodiversity of fungi in nasal mucus. In: IUMS - The World of Microbes, Xth International 
Congress of Mycology, Abstracts, EDK Medical and Scientific International Publisher, Paris 
2002, p 79 
35. Imokawa,S., Sato,A., Taniguchi,M., Imamura,M., Shirai,T., Suda,T., Iwata,M., Gemma,H.: 
Two cases of acute eosinophilic pneumonia with precipitating antibody against Trichosporon 
cutaneum and Trichoderma viride. Nihon Kyobu Shikkan Gakkai Zasshi (Japan) 31, 352-359 
(1993). 
36. Mouri,M., Nambu,Y., Horii,H., Kobayashi,Y., Yamanouchi,K., Sakurai,S., Toga,H., Ohya,N.: 
Case report and review of literature on seasonal distribution and pathogenesis of acute 
eosinophilic pneumonia in Japan. Nihon Kyobu Shikkan Gakkai Zasshi (Japan) 31, 1568-
1584 (1993). 
37. Larsen,F.O., Clementsen,P., Hansen,M., Maltbaek,N., Gravensen,S., Stahl Skov,P., Norn,S.: 
The indoor microfungus Trichoderma viride potentiates histamine release from human 
bronchoalveolar cells. APMIS 104, 673-679 (1996). 
38. Antal,Z., Kredics,L., Dóczi,I., Manczinger,L., Kevei,F., Nagy,E.: The physiological features of 
opportunistic Trichoderma strains. Acta Microbiol Immunol Hung 49, 393 (2002). 
39. Rinaldi,M.G., Howell,A.W.: Antifungal antimicrobics: laboratory evaluation. In: 
Wentworth,B. (ed): Diagnostic procedures for mycotic and parasitic infections. 7th ed. 
American Public Health Association, Washington, D.C. 1988, pp 325-356  
 40. Etest technical guide 10: Antifungal susceptibility testing of moulds. AB Biodisk, Solna, 
Sweden (1999) 
41. National Committee for Clinical Laboratory Standards. Reference method for broth dilution 
antifungal susceptibility testing of conidium forming filamentous fungi: Proposed standard 
M38-P. National Committee for Clinical Laboratory Standards, Wayne, Pa. 1998 
42. Pujol,I., Guarro,J., Llop,C., Soler,L., Fernández-Ballart,J.: Comparison study of broth 
macrodilution and microdilution antifungal susceptibility tests for the filamentous fungi. 
Antimicrob Agents Chemother 40, 2106-2110 (1996). 
43. Shadomy,S., Pfaller,M.: Laboratory studies with antifungal agents: susceptibility tests and 
quantitation in body fluids. In: Balows,A. et al. (ed): Manual of clinical microbiology, 5th ed. 
American Society for Microbiology, Washington, D.C. 1991, pp 1173-1183  
44. Drouhet,E., Dupont,B., Improvosi,L., Viviani,M.A., Tortorano,A.M.: Disc agar diffusion and 
microplate automatized technics for in vitro evaluation of antifungal agents on yeasts and 
sporulated pathogenic fungi. In: Iwata,K., Vanden Bossche,H. (eds): In vitro and in vivo 
evaluation of antifungal agents. Elsevier Science Press, Paris 1986, pp 31-49  
45. Naár,Z., Kecskés,M.: Factors influencing the competitive saprophytic ability of Trichoderma 
species. Microbiol Res 153, 119-129 (1998). 
46. Antal,Z., Manczinger,L., Szakács,G., Tengerdy,R.P., Ferenczy,L.: Colony growth, in vitro 
antagonism and secretion of extracellular enzymes in cold-tolerant strains of Trichoderma 
species. Mycol Res 104, 545-549 (2000). 
47. Kredics,L., Antal,Z., Manczinger,L.: Influence of water potential on growth, enzyme 
secretion and in vitro enzyme activities of Trichoderma harzianum at different temperatures. 
Curr Microbiol 40, 310-314 (2000). 
48. Kredics,L., Dóczi,I., Antal,Z., Manczinger,L.: Effect of heavy metals on growth and 
extracellular enzyme activities of mycoparasitic Trichoderma strains. Bull Environ Contam 
Toxicol 66, 249-254 (2001). 
49. Manczinger,L., Molnár,A., Kredics,L., Antal,Z.: Production of bacteriolytic enzymes by 
mycoparasitic Trichoderma strains. World J Microbiol Biotechnol 18, 147-150 (2002). 
50. Goldfarb,B., Nelson,E.E., Hansen,E.M.: Trichoderma spp.: Growth rates and antagonism to 
Phellinus weirii in vitro. Mycologia 81, 375-381 (1989). 
51. Widden,P.: The effects of temperature on competition for spruce needles among sympatric 
species of Trichoderma. Mycologia 76, 873-883 (1984). 
52. Kredics,L., Antal,Z., Manczinger,L., Kevei,F., Nagy,E.: Proteolytic enzyme profiles of 
clinical Trichoderma isolates. Acta Microbiol Immunol Hung 49, 416-417 (2002). 
53. Kuhls,K., Lieckfeldt,E., Börner,T., Guého,E.: Molecular reidentification of human 
pathogenic Trichoderma isolates as Trichoderma longibrachiatum and Trichoderma 
citrinoviride. Med Mycol 37, 25-33 (1999). 
54. Hogan,L.H., Klein,B.S., Levitz,S.M.: Virulence factors of medically important fungi. Clin 
Microbiol Rev 9, 469-488 (1996). 
 
Addresses of the authors: 
Corresponding author: Dr. László Kredics, Hungarian Academy of Sciences and University 
of Szeged, Microbiological Research Group, P.O. Box 533, H-6701 Szeged, Hungary, Fax: 
06 62 544 823, E-mail: kredics@bio.u-szeged.hu 
Dr. Zsuzsanna Antal: Hungarian Academy of Sciences and University of Szeged, 
Microbiological Research Group, P.O. Box 533, H-6701 Szeged, Hungary, Fax: 06 62 544 
823 
Ilona Dóczi, Prof. Elisabeth Nagy: Department of Clinical Microbiology, Faculty of 
Medicine, University of Szeged, Somogyi Béla tér 1, H-6725 Szeged, Hungary 
Dr. László Manczinger, Dr. Ferenc Kevei: Department of Microbiology, Faculty of 
Sciences, University of Szeged, P.O. Box 533, H-6701 Szeged, Hungary. Fax: 06 62 544 823
Table I  
Case reports about Trichoderma infections in the literature 
 Age/Sex Clinical diagnosis Source Etiology Therapy Outcome Reference 
 
82/M CAPD peritonitis Peritoneal fluid T. harzianum K, 5FC Death [10] 
 
63/F CAPD peritonitis Peritoneal fluid T. koningii Catheter removal, M Survival [11] 
 
41/M CAPD peritonitis Peritoneal fluid T. koningii F, 5FC, AB Death [12] 
 
48/M CAPD peritonitis Peritoneal fluid, autopsy T. longibrachiatum AB Death [13] 
 
33/M APD peritonitis Peritoneal fluid T. pseudokoningii Catheter removal Survival [14] 
 
47/M CAPD peritonitis Peritoneal fluid, autopsy T. viride AB Death [15] 
 
44/M CAPD peritonitis Peritoneal fluid T. viride AB Death [16] 
 
60/M CAPD peritonitis Peritoneal fluid Trichoderma sp. Catheter removal, K Survival [17] 
 
45/F TX/Lung and skin dissemination Bronchoalveolar lavage, skin biopsy T. pseudokoningii F, AB, 5FC Death [18] 
 
29/M TX/Disseminated infection Lung, liver, intestinal wall, autopsy T. longibrachiatum AB, I, liposomal AB Death [19] 
 
44/F TX/Abdominal dissemination Peritoneal fluid, haematoma T. viride Surgery, AB, F Death [20] 
 
29/F TX/Acute invasive sinusitis Sinus debridement T. longibrachiatum Surgery, AB, I Survival [21] 
 
68/M TX/Disseminated infection Brain and lung abscesses, autopsy T. harzianum  - Death [22] 
 
11/M Skin infection Skin biopsy T. longibrachiatum AB Survival [23] 
 
17/F Brain abscess Brain biopsy, cerebral pus T. longibrachiatum Surgery, AB, 5FC, K, I Survival [24] 
 
12/ND Otitis externa Ear discharge T. longibrachiatum nystatin, polymyxin B Survival [25] 
 
46/M Pulmonary mycetoma Sputum, lung biopsy T. viride Surgery ND [28] 
 
66/M Endocarditis Aortic conduit Trichoderma sp. Surgery, antifungal drugs  Survival [30] 
 
26/F Fungemia by contaminated saline Blood Trichoderma viride AB Survival [33] 
 
M = male, F = female; APD = automated peritoneal dialysis, CAPD = chronic ambulatory peritoneal dialysis; 5FC = 5-fluorocytosine, AB = 
amphotericin B, F = fluconazole, I = itraconazole, K = ketoconazole, M = miconazole; TX = transplant; ND = no data available 
Table II 
Antifungal susceptibilities of clinical Trichoderma isolates 
 
Isolate Method Antifungal agent MIC (µg/ml) Reference 
T. longibrachiatum Macrobroth dilution 5FC >322.75 [21] 
UAMH 7955 [39] AB 1.16  
  F 80  
  I 0.3  
 Etest [40] AB 1 [38] 
  F >256  
  I 32  
  K 0.125  
 Disk method V 
 
*7 mm  
T. longibrachiatum NCCLS M-38P [41] 5FC >256 [19] 
UAMH 7956  AB 2.0  
  F 16  
  I 1.0  
 Etest [40] AB 2 [38] 
  F 64  
  I 16  
  K 0.25  
 Disk method V 
 
*9 mm  
T. longibrachiatum Etest [40] AB 2 [38] 
UAMH 9515  F >256  
  I 16  
  K 0.5  
 Disk method V 
 
*9 mm  
T. longibrachiatum NCCLS broth 5FC >64 [23] 
ATCC 201044 macrodilution AB 2  
  F >64  
  I 2  
 Etest [40] AB 2 [38] 
  F 64  
  I 0.5  
  K 0.008 
 
 
T. longibrachiatum Etest [40] AB 2 [38] 
ATCC 208859  F >256  
  I 8  
  K 0.25 
 
 
T. longibrachiatum Broth dilution 5FC 50 [24] 
IP-93 1192  AB 2.5  
  F 12.5  
  I 1.25  
 Disk method K 
 
*34 mm  
T. longibrachiatum Broth dilution AB 
 
5 [13] 
T. longibrachiatum Etest AB 24 [25] 
  I 
 
32  
T. longibrachiatum NCCLS M-38P [41] AB 0.5-2 [31] 
(5 isolates)  I >8  
  V 2  
 Etest AB 1.0-4 [32] 
  I >8  
Table II (continued) 
Isolate Method Antifungal agent MIC (µg/ml) Reference 
T. citrinoviride Etest [40] AB 2 [38] 
UAMH 9573  F 64  
  I 32  
  K 0.25  
 Disk method V 
 
*9 mm  
T. harzianum Microdilution 5FC 256 [22] 
CBS 102174 [42] AB 2  
  F 128  
  I 32  
  K 8  
  M 
 
8  
T. koningii Broth microdilution 5FC 16.0 [12] 
CM 382 [43] AB 4.0  
  F 128.0  
  K 1.0  
  M ≤0.25  
 Etest [40] AB 8 [38] 
  F >256  
  I 2  
  K 0.25  
 Disk method V 
 
*8 mm  
T. koningii ND 5FC ND, resistant [11] 
  AB ND, resistant  
  K ND, susceptible  
  M 
 
ND, susceptible  
T. pseudokoningii Broth microdilution 5FC >100 [18] 
IP-92 2110 [44] AB 0.09  
  F 25  
  I 0.18  
  M 0.09 
 
 
T. viride Broth dilution 5FC 100 [15] 
  AB 0.78  
  K 1.56 
 
 
T. viride Broth dilution  5FC >50 [20] 
  AB 3.1  
  F 25  
  I 1.6  
  K 0.8  
 
5FC = 5-fluorocytosine, AB = amphotericin B, F = fluconazole, I = itraconazole,  
K = ketoconazole, M = miconazole, V = voriconazole 
ND = no specific data, * = diameter of inhibition zone 
ATCC = American Type Culture Collection 
CBS = Centraalbureau voor Schimmelcultures 
CM = Centro Nacional de Microbiologia, Immunologia y Virologia Sanitaria 
IP = Institut Pasteur 
UAMH = University of Alberta Microfungus Collection and Herbarium 
